Share on LinkedInShare on LinkedIn

ARTICLE · 24 JUNE 2009

Drug Companies Abandon Merger Plans After FTC Challenge

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

Just two weeks after the FTC filed a complaint seeking an injunction to stop the proposed $3.1 billion acquisition by Australia-based CSL Limited of Talecris Biotherapeutics Holding Corporation, the parties have withdrawn their plans for a merger.

United StatesAntitrust/Competition Law

Just two weeks after the FTC filed a complaint seeking an injunction to stop the proposed $3.1 billion acquisition by Australia-based CSL Limited of Talecris Biotherapeutics Holding Corporation, the parties have withdrawn their plans for a merger. The announcement, made on June 8, 2009, came despite the parties' initial statements that they would "vigorously oppose the FTC's actions." The FTC complaint and its aggressive public statements about the proposed deal may exemplify a new hard-ball approach to enforcement under the agency's new leadership.

The proposed merger, announced last August, would have combined two of the world's three largest producers of plasma-derivative protein therapies used to treat immune, pulmonary, and other diseases. The FTC's complaint, filed May 27 in the U.S. District Court for the District of Columbia, alleged that a merger of CSL and Talecris would substantially reduce competition in the U.S. markets for four plasma-derivative protein

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from